VEGFA mRNA for regenerative treatment of heart failure

Nat Rev Drug Discov. 2022 Jan;21(1):79-80. doi: 10.1038/s41573-021-00355-6.

Anna Collén¹, Nils Bergenhem², Leif Carlsson³, Kenneth R Chien⁴, Stephen Hoge⁵, Li-Ming Gan^{3

6

7}, Regina Fritsche-Danielson³

¹ Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. anna.collen@astrazeneca.com.
² Alliance Management, Business Development, BioPharmaceuticals R&D, AstraZeneca, Boston, MA, USA.
³ Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
⁴ Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
⁵ Moderna Inc., Cambridge, MA, USA.
⁶ Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
⁷ Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.

No abstract available

Publication types